Skip to main content
. Author manuscript; available in PMC: 2022 Jan 1.
Published in final edited form as: Int J Radiat Biol. 2020 Mar 2;97(8):1109–1120. doi: 10.1080/09553002.2020.1730012

Figure 4.

Figure 4.

Regorafenib inhibits tube formation in Human Umbilical Vein Endothelial Cells (HUVECs). (A). Microscopic images of HUVECs showing the changes in tube formation when incubated with or without Regorafenib (50 nM or 75 nM) for 24 h. Distinct disruption of tube network can be seen from the images of HUVECs treated with Regorafenib. (B). Cell viability of HUVECs at 24-h post-Regorafenib treatment (50 nM or 75 nM) compared to DmSO control. *p ≤ .05.